Effect of caffeine on the expression of cytochrome P450 1A2, adenosine A2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum

Brain Research

Volumn 1283, Issue , 2009, Pages 115-126

  Singh, Seema ^a   Singh, Kavita ^a   Gupta, Satya Prakash ^a   Patel, Devendra Kumar ^a   Singh, Vinod Kumar ^b   Singh, Raj Kumar ^b   Singh, Mahendra Pratap ^a  

^a CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

^b KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

1 Methyl 4 phenyl 1, 2, 3, 6 tetrahydropyridine; Adenosine A2A receptor; Caffeine; Cytochrome P450 1A2; Dopamine transporter; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENOSINE A2A RECEPTOR; CAFFEINE; CYTOCHROME P450 1A2; DOPAMINE TRANSPORTER; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALYSIS; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE PREDISPOSITION; DRUG EFFECT; ENZYME ACTIVITY; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CAFFEINE; CORPUS STRIATUM; CYTOCHROME P-450 CYP1A2; CYTOPROTECTION; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; MALE; MICE; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; RECEPTOR, ADENOSINE A2A; TYROSINE 3-MONOOXYGENASE;

ANIMALIA; MUS;

EID: 67651099082     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.06.002     Document Type: Article

References (56)

1. Ascherio A., Zhang S.M., Hernan M.A., Kawachi I., Colditz G.A., Speizer F.E., and Willett W.C. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann. Neurol. 50 (2001) 56-63
2. Avshalumov M.V., Chen B.T., Koos T., Tepper J.M., and Rice M.E. Endogenous hydrogen peroxide regulates the excitability of midbrain dopamine neurons via ATP-sensitive potassium channels. J. Neurosci. 25 (2005) 4222-4231
3. Bousquet M., Saint-Pierre M., Julien C., Salem N.Jr., Cicchetti F., and Calon F. Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson's disease. FASEB J. 22 (2008) 1213-1225
4. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
5. Canals M., Marcellino D., Fanelli F., Ciruela F., de Benedetti P., Goldberg S.R., Neve K., Fuxe K., Agnati L.F., Woods A.S., Ferre S., Lluis C., Bouvier M., and Franco R. Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J. Biol. Chem. 278 (2003) 46741-46749
6. Carrillo J.A., and Benitez J. CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine. Br. J. Clin. Pharmacol. 41 (1996) 605-608
7. Chen J.F., Xu K., Petzer J.P., Staal R., Xu Y.H., Beilstein M., Sonsalla P.K., Castangoli K., Castangoli N.J., and Scharzchild M.A. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci. 21 (2001) RC143
8. Chen X., Lan X., Roche I., Liu R., and Geiger J.D. Caffeine protects against MPTP-induced blood-brain barrier dysfunction in mouse striatum. J Neurochem. 107 (2008) 1147-1157
9. Choudhary D., Jansson I., Schenkman J.B., Sarfarazi M., and Stoilov I. Comparative expression profiling of 40 mouse cytochrome P450 genes in embryonic and adult tissues. Arch. Biochem. Biophys. 414 (2003) 91-100
10. Ciruela F., Burgueno J., Casado V., Canals M., Marcellino D., Goldberg S.R., Bader M., Fuxe K., Agnati L.F., Lluis C., Franco R., Ferre S., and Woods A.S. Combining mass spectrometry and pull-down techniques for the study of receptor heteromerization. Direct epitope-epitope electrostatic interactions between adenosine A2A and dopamine D2 receptors. Anal. Chem. 76 (2004) 5354-5363
11. El Yacoubi M., Ledent C., Menard J.F., Parmentier M., Costentin J., and Vaugeois J.M. The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A(2A) receptors. Br. J. Pharmacol. 129 (2000) 1465-1473
12. Ferre S., Fuxe K., von Euler G., Johansson B., and Fredholm B.B. Adenosine-dopamine interactions in the brain. Neuroscience 51 (1992) 501-512
13. Fredholm B.B. Connection between caffeine, adenosine receptors and dopamine. Coffee reduces the risk of Parkinson disease. Lakartidningen 101 (2004) 2552-2555
14. Fredholm B.B., Battig K., Holmen J., Nehlig A., and Zvartau E.E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev. 51 (1999) 83-133
15. Fuhr U., Anders E.M., Mahr G., Sorgel F., and Staib A.H. Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob. Agents Chemother. 36 (1992) 942-948
16. Fuxe K., Ferre S., Zoli M., and Agnati L.F. Integrated events in central dopamine transmission as analyzed at multiple levels. Evidence for intramembrane adenosine A2A/dopamine D2 and adenosine A1/dopamine D1 receptor interactions in the basal ganglia. Brain Res. Brain Res. Rev. 26 (1998) 258-273
17. Gainetdinov R.R., Fumagalli F., Jones S.R., and Caron M.G. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J. Neurochem. 69 (1997) 1322-1325
18. Gerlach M., and Riederer P. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J. Neural. Transm. 103 (1996) 987-1041
19. Goasduff T., Dreano Y., Guillois B., Menez J.F., and Berthou F. Induction of liver and kidney CYP1A1/1A2 by caffeine in rat. Biochem. Pharmacol. 52 (1996) 1915-1919
20. Gorbatyuk O.S., Li S., Sullivan L.F., Chen W., Kondrikova G., Manfredsson F.P., Mandel R.J., and Muzyczka N. The phosphorylation state of Ser-129 in human α-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 763-768
21. Gu L., Gonzalez F.J., Kalow W., and Tang B.K. Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by cDNA expressed human CYP1A2 and CYP2E1. Pharmacogenetics 2 (1992) 73-77
22. Johannessen J.N., Chiueh C.C., Burns R.S., and Markey S.P. Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects. Life Sci. 36 (1985) 219-224
23. Jones G. Caffeine and other sympathomimetic stimulants: modes of action and effects on sports performance. Essays Biochem. 44 (2008) 109-123
24. Kalow W., and Tang B.K. The use of caffeine for enzyme assays; a critical appraisal. Clin. Pharmacol. Ther. 53 (1993) 503-514
25. Kurokawa M., Koga K., Kase H., Nakamura J., and Kuwana Y. Adenosine A2a receptor-mediated modulation of striatal acetylcholine release in vivo. J. Neurochem. 66 (1996) 1882-1888
26. Kurosaki R., Muramatsu Y., Watanabe H., Michimata M., Matsubara M., Imai Y., and Araki T. Role of dopamine transporter against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice. Metab. Brain Dis. 18 (2003) 139-146
27. Lindskog M., Svenningsson P., Pozzi L., Kim Y., Fienberg A.A., Bibb J.A., Fredholm B.B., Nairn A.C., Greengard P., and Fisone G. Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine. Nature 418 (2002) 774-778
28. Liu B., Xie J.X., Tsang L.L., Rowlands D.K., Ho L.S., Gou Y.L., Chung Y.W., and Chan H.C. Bak Foong protects dopaminergic neurons against MPTP-induced neurotoxicity by its anti-apoptotic activity. Cell Biol. Int. 32 (2008) 86-92
29. Liu L.X., Chen W.F., Xie J.X., and Wong M.S. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease. Neurosci. Res. 60 (2008) 156-161
30. Mao X., Chai Y., and Lin Y.F. Dual regulation of the ATP-sensitive potassium channel by caffeine. Am. J. Physiol. Cell Physiol. 292 (2007) C2239-2258
31. McCall A.L., Millington W.R., and Wurtman R.J. Blood-brain barrier transport of caffeine: dose-related restriction of adenine transport. Life Sci. 31 (1982) 2709-2715
32. Mochizuki H., Hayakawa H., Migita M., Shibata M., Tanaka R., Suzuki A., Shimo-Nakanishi Y., Urabe T., Yamada M., Tamayose K., Shimada T., Miura M., and Mizuno Y. An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 10918-10923
33. Monopoli A., Lozza G., Forlani A., Mattavelli A., and Ongini E. Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. NeuroReport 9 (1998) 3955-3959
34. Mori A., Shindou T., Ichimura M., Nonaka H., and Kase H. The role of adenosine A2a receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons. J. Neurosci. 16 (1996) 605-611
35. Nakanishi N., Onozawa S., Matsumoto R., Kurihara K., Ueha T., Hasegawa H., and Minami N. Effects of protein kinase inhibitors and protein phosphatase inhibitors on cyclic AMP-dependent down-regulation of vesicular monoamine transport in pheochromocytoma PC12 cells. FEBS Lett. 368 (1995) 411-414
36. Nakaso K., Ito S., and Nakashima K. Caffeine activates the PI3K/Akt pathway and prevents apoptotic cell death in a Parkinson's disease model of SH-SY5Y cells. Neurosci. Lett. 432 (2008) 146-150
37. Ochi M., Koga K., Kurokawa M., Kase H., Nakamura J., and Kuwana Y. Systemic administration of adenosine A(2A) receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study. Neuroscience 100 (2000) 53-62
38. Patel S., Singh K., Singh S., and Singh M.P. Gene expression profiles of mouse striatum in control and maneb - paraquat induced Parkinson's disease phenotype: validation of differentially expressed energy metabolizing transcripts. Mol. Biotechnol. 40 (2008) 59-68
39. Pierri M., Vaudano E., Sager T., and Englund U. KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. Neuropharmacology 48 (2005) 517-524
40. Przedborski S., Jackson Lewis V., Djaldetti R., Liberatore G., Vila M., Vukosavic S., and Almer G. The Parkinsonian-toxin MPTP: action and mechanism. Restor. Neurol. Neurosci. 16 (2000) 135-142
41. Rajeswari A., and Sabesan M. Neuropathological changes induced by neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in male Swiss albino mice. Toxicol. Ind. Health 24 (2008) 189-194
42. Ravina B.M., Fagan S.C., Hart R.G., Hovinga C.A., Murphy D.D., Dawson T.M., and Marler J.R. Neuroprotective agents for clinical trials in Parkinson-s disease: a systematic assessment. Neurology 60 (2003) 1234-1240
43. Riachi N.J., Harik S.I., Kalaria R.N., and Sayre L.M. On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. II. Susceptibility among mammalian species correlates with the toxin's metabolic patterns in brain microvessels and liver. J. Pharmacol. Exp. Ther. 244 (1988) 443-448
44. Richardson P.J., Kase H., and Jenner P.G. Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson-s disease. Trends Pharmacol. Sci. 18 (1997) 338-344
45. Singh S., Singh K., Patel S., Patel D.K., Singh C., Nath C., and Singh M.P. Nicotine and caffeine-mediated modulation in the expression of toxicant responsive genes and vesicular monoamine transporter-2 in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine'induced Parkinson's disease phenotype in mouse. Brain Res. 1207 (2008) 193-207
46. Svenningsson P., and Fredholm B.B. Exciting news about A2A receptors. Neurology 61 (2003) S10-S11
47. Tanner C.M., Ottman R., Goldman S.M., Ellenberg J., Chan P., Mayeux R., and Langston J.W. Parkinson disease in twins: an etiologic study. JAMA 281 (1999) 341-346
48. Tarditi A., Camurri A., Varani K., Borea P.A., Woodman B., Bates G., Cattaneo E., and Abbracchio M.P. Early and transient alteration of adenosine A2A receptor signaling in a mouse model of Huntington disease. Neurobiol. Dis. 23 (2006) 44-53
49. Thiriet N., Amar L., Toussay X., Lardeux V., Ladenheim B., Becker K.G., Cadet J.L., Solinas M., and Jaber M. Environmental enrichment during adolescence regulates gene expression in the striatum of mice. Brain Res. 1222 (2008) 31-41
50. Ulanowska K., Piosik J., Gwizdek-Wisniewska A., and We Grzyn G. Formation of stacking complexes between caffeine (1,2,3-trimethylxanthine) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine may attenuate biological effects of this neurotoxin. Bioorg. Chem. 33 (2005) 402-413
51. Upadhyay G., Kumar A., and Singh M.P. Effect of silymarin on pyrogallol-and rifampicin-induced hepatotoxicity in mouse. Eur. J. Pharmacol. 565 (2007) 190-201
52. Vieregge P., Hagenah J., Heberlein I., Klein C., and Ludin H.P. Parkinson's disease in twins: a follow-up study. Neurology 53 (1999) 566-572
53. Wirdefeldt K., Gatz M., Schalling M., and Pedersen N.L. No evidence for heritability of Parkinson disease in Swedish twins. Neurology 63 (2004) 305-311
54. Xu K., Xu Y., Brown-Jermyn D., Chen J.F., Ascherio A., Dluzen D.E., and Schwarzschild M.A. Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Neurosci. 26 (2006) 535-541
55. Xu K., Xu Y.H., Chen J.F., and Schwarzschild M.A. Caffeine-s neuro-protection against 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Neurosci. Lett. 322 (2002) 13-16
56. Xu Z., Cawthon D., McCastlain K.A., Slikker Jr. W., and Ali S.F. Selective alterations of gene expression in mice induced by MPTP. Synapse 55 (2005) 45-51